-Biochemical screening for neural tube defects and chromosome abnormalities
, particularly Down syndrome, has developed over the past 30 years and has
become a mainstay of obstetric screening. Recent advances have improved the
sensitivity of Down syndrome screening to approximately 65%, but much cont
roversy remains as to the best approaches for further improvement.